rdf:type |
|
lifeskim:mentions |
|
pubmed:issue |
1A
|
pubmed:dateCreated |
2006-2-14
|
pubmed:abstractText |
The effects of the bisphosphonate derivative zoledronic acid (ZA) on the circulating levels of matrix metalloproteinase-2 (MMP-2), matrix metallo-proteinases-9 (MMP-9), cathepsin B (Cath B) and urokinase-type plasminogen activator (uPA) in patients with bone metastasis (BMTS) and the possible correlation with the symptomatic response induced by this drug in these patients were evaluated.
|
pubmed:language |
eng
|
pubmed:journal |
|
pubmed:citationSubset |
IM
|
pubmed:chemical |
|
pubmed:status |
MEDLINE
|
pubmed:issn |
0250-7005
|
pubmed:author |
|
pubmed:issnType |
Print
|
pubmed:volume |
26
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
23-6
|
pubmed:dateRevised |
2008-11-21
|
pubmed:meshHeading |
pubmed-meshheading:16475674-Aged,
pubmed-meshheading:16475674-Aged, 80 and over,
pubmed-meshheading:16475674-Bone Density Conservation Agents,
pubmed-meshheading:16475674-Bone Neoplasms,
pubmed-meshheading:16475674-Breast Neoplasms,
pubmed-meshheading:16475674-Cathepsin B,
pubmed-meshheading:16475674-Diphosphonates,
pubmed-meshheading:16475674-Female,
pubmed-meshheading:16475674-Humans,
pubmed-meshheading:16475674-Imidazoles,
pubmed-meshheading:16475674-Male,
pubmed-meshheading:16475674-Matrix Metalloproteinase 2,
pubmed-meshheading:16475674-Matrix Metalloproteinase 9,
pubmed-meshheading:16475674-Middle Aged,
pubmed-meshheading:16475674-Prostatic Neoplasms,
pubmed-meshheading:16475674-Urokinase-Type Plasminogen Activator
|
pubmed:articleTitle |
Effects of zoledronic acid on proteinase plasma levels in patients with bone metastases.
|
pubmed:affiliation |
Laboratory of Experimental Chemotherapy and Tumor Markers, Policlinico Universitario P. Giaccone, 90127 Palermo, Italy. gleto@unipa.it
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, Non-U.S. Gov't
|